A clinical trial of eftilagimod alpha in patients with metastatic breast cancer in China
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2018
Price : $35 *
At a glance
- Drugs Eftilagimod alpha (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 01 Nov 2018 According to an Immutep media release, first patient dosed in October 2018.
- 01 Nov 2018 Status changed from planning to recruiting, according to an Immutep media release.
- 17 Apr 2018 New trial record